Interview with Allison Betof Warner, MD, PhD: TIL Therapy
The following is an edited and shortened version of our recent interview with Allison Betof Warner, MD, PhD about the…
04/11/2024
Interview with Allison Betof Warner, MD, PhD: TIL Therapy
The following is an edited and shortened version of our recent interview with Allison Betof Warner, MD, PhD about the…
|
04/11/2024
In Plain English: Tumor-Infiltrating Lymphocyte (“TIL”) Therapy for Advanced Melanoma
By Kim Margolin, M.D., FACP, FASCO Note: We are rerunning an update on this TIL therapy article that originally ran…
|
|
03/15/2024
The FDA Approval of TIL Therapy and What it Means for Advanced Melanoma
An exciting new development in melanoma treatment is the recent FDA approval of Lifileucel (AMTAVGI) therapy, which harnesses the power…
|
|
02/17/2024
Iovance Biotherapeutics Announces Approval for TIL Therapy
The Food and Drug Administration approval provides another option for advanced, refractory melanoma February 16, 2024 (Richmond, California) The FDA…
|
|
01/18/2024
FDA Approves First AI-Powered Skin Cancer Diagnostic Tool
FDA Approves First AI-Powered Skin Cancer Diagnostic Tool The DermaSensor device demonstrates a high rate of sensitivity in the detection…
|
|
10/23/2023
Immunocore Presents Three-Year Overall Survival Data from the KIMMTRAK Phase 3 Trial
Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial Published: Oct 21, 2023 Data published in New…
|
|
10/15/2023
Opdivo® (nivolumab) Approved as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma
October 13, 2023 17:30 ET| Source: Bristol Myers Squibb In the Phase 3 CheckMate -76K trial, Opdivo demonstrated a statistically significant…
|
|
09/17/2023
Notes from the Lab: Novel targets for immune checkpoint inhibitors
By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory Survival rates of patients with melanoma have drastically improved in the…
|
08/15/2023
Clinical Trials Catch Up
Welcome to our new interview series called Clinical Trials Catch Up, an article delivered in a question-and-answer format designed to…
|
08/01/2023
AIM’s Latest Newsletter: The Research Edition, July 2023
This month’s newsletter focuses on the latest news and scientific breakthroughs in melanoma research. This edition features: Letter from AIM’s…
|
Entradas recientes
Apr. 16, 2024
Navigating the Journey Together – Conversations with Melanoma Caregivers
Apr. 12, 2024
May is Brain Tumor Awareness Month
Apr. 11, 2024
President’s Letter | April 2024
Apr. 11, 2024
Celebrating a Milestone: 20 Years of the Dallas Steps Against Melanoma Walk
Apr. 11, 2024